206 related articles for article (PubMed ID: 35348362)
1. A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge
Hong J; Zhong L; Zheng Q; Wu Q; Zha Z; Wei D; Chen H; Zhang W; Zhang S; Huang Y; Chen K; Chen J; Li S; Zeng MS; Zeng YX; Xia N; Zhang X; Xu M; Chen Y
J Virol; 2022 Apr; 96(8):e0007522. PubMed ID: 35348362
[TBL] [Abstract][Full Text] [Related]
2. Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection.
Hong J; Zhong L; Liu L; Wu Q; Zhang W; Chen K; Wei D; Sun H; Zhou X; Zhang X; Kang YF; Huang Y; Chen J; Wang G; Zhou Y; Chen Y; Feng QS; Yu H; Li S; Zeng MS; Zeng YX; Xu M; Zheng Q; Chen Y; Zhang X; Xia N
Cell Rep Med; 2023 Nov; 4(11):101296. PubMed ID: 37992686
[TBL] [Abstract][Full Text] [Related]
3. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
4. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
5. An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.
Snijder J; Ortego MS; Weidle C; Stuart AB; Gray MD; McElrath MJ; Pancera M; Veesler D; McGuire AT
Immunity; 2018 Apr; 48(4):799-811.e9. PubMed ID: 29669253
[TBL] [Abstract][Full Text] [Related]
6. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.
Wei CJ; Bu W; Nguyen LA; Batchelor JD; Kim J; Pittaluga S; Fuller JR; Nguyen H; Chou TH; Cohen JI; Nabel GJ
Sci Transl Med; 2022 May; 14(643):eabf3685. PubMed ID: 35507671
[TBL] [Abstract][Full Text] [Related]
7. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
8. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus.
Edwards KR; Schmidt K; Homad LJ; Kher GM; Xu G; Rodrigues KA; Ben-Akiva E; Abbott J; Prlic M; Newell EW; De Rosa SC; Irvine DJ; Pancera M; McGuire AT
Cell Rep Med; 2024 Jun; 5(6):101587. PubMed ID: 38781964
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition.
Chen WH; Kim J; Bu W; Board NL; Tsybovsky Y; Wang Y; Hostal A; Andrews SF; Gillespie RA; Choe M; Stephens T; Yang ES; Pegu A; Peterson CE; Fisher BE; Mascola JR; Pittaluga S; McDermott AB; Kanekiyo M; Joyce MG; Cohen JI
Immunity; 2022 Nov; 55(11):2135-2148.e6. PubMed ID: 36306784
[TBL] [Abstract][Full Text] [Related]
11. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus.
Zhu QY; Shan S; Yu J; Peng SY; Sun C; Zuo Y; Zhong LY; Yan SM; Zhang X; Yang Z; Peng YJ; Shi X; Cao SM; Wang X; Zeng MS; Zhang L
Nat Commun; 2021 Nov; 12(1):6624. PubMed ID: 34785638
[TBL] [Abstract][Full Text] [Related]
12. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
13. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies against EBV gp42 show potent
Wu Q; Zhong L; Wei D; Zhang W; Hong J; Kang Y; Chen K; Huang Y; Zheng Q; Xu M; Zeng MS; Zeng YX; Xia N; Zhao Q; Krummenacher C; Chen Y; Zhang X
Emerg Microbes Infect; 2023 Dec; 12(2):2245920. PubMed ID: 37542379
[TBL] [Abstract][Full Text] [Related]
15. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes.
Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG
Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598
[TBL] [Abstract][Full Text] [Related]
16. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
17. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
18. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion.
Zhang X; Hong J; Zhong L; Wu Q; Zhang S; Zhu Q; Chen H; Wei D; Li R; Zhang W; Zhang X; Wang G; Zhou X; Chen J; Kang Y; Zha Z; Duan X; Huang Y; Sun C; Kong X; Zhou Y; Chen Y; Ye X; Feng Q; Li S; Xiang T; Gao S; Zeng MS; Zheng Q; Chen Y; Zeng YX; Xia N; Xu M
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2202371119. PubMed ID: 35917353
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.
Malhi H; Homad LJ; Wan YH; Poudel B; Fiala B; Borst AJ; Wang JY; Walkey C; Price J; Wall A; Singh S; Moodie Z; Carter L; Handa S; Correnti CE; Stoddard BL; Veesler D; Pancera M; Olson J; King NP; McGuire AT
Cell Rep Med; 2022 Jun; 3(6):100658. PubMed ID: 35705092
[TBL] [Abstract][Full Text] [Related]
20. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]